Virpax Pharmaceuticals

Virpax Pharmaceuticals, Inc. is a preclinical stage biopharmaceutical company, which engages in the development of branded, non-addictive pain management products. Its products include metered-dose spray, liposomal gel encapsulates, and intranasal spray. The company was founded by Anthony P. Mack and Jeffrey A. Gudin in 2016 and and is headquartered in Berwyn, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Leadership Transition.

Virpax Pharmaceuticals Announces Leadership Transition

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Reports 2023 Third Quarter Results and Recent Developments.

Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent Developments

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Review.

Virpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Review

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Extension of CRADA with the U.S. Army Institute of Surgical Research.

Virpax Pharmaceuticals Announces Extension of CRADA with the U.S. Army Institute of Surgical Research

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Results of Probudur™ Dose Escalation Studies.

Virpax Pharmaceuticals Announces Results of Probudur™ Dose Escalation Studies

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax to Present at the LD Micro Main Event XVI.

Virpax Pharmaceuticals to Present at the LD Micro Main Event XVI

LAVAL, Québec--(BUSINESS WIRE)-- #Altasciences--Altasciences is pleased to have been chosen by Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) (“Virpax”), a company specializing in developing non-addictive products for pain management, PTSD, central nervous system (CNS) disorders, and viral barrier indications, to conduct preclinical studies in support of their development of quaternary ammonium palmitoyl glycol chitosan (GCPQ, under the trade name of AnQlar™). AnQlar is a nanoparticle intended to help prevent the.

Altasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like Viruses

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces the Formation of Novvae™ Pharmaceuticals.

Virpax Pharmaceuticals Announces the Formation of Novvae™ Pharmaceuticals

Scilex Holding Co

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that it has received a ruling on the lawsuit filed by Scilex Pharmaceuticals (NASDAQ:SCLX) and Sorrento Therapeutics, the now bankrupt majority owner of Scilex Pharmaceuticals. The Court found in.

Virpax Pharmaceuticals Updates on Litigation

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax to Present at H.C. Wainwright 25th Annual Global Investment Conference.

Virpax® Pharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference

BERWYN, Pa.--(BUSINESS WIRE)-- #earnings--Virpax Reports 2023 Second Quarter Results and Recent Developments.

Virpax Pharmaceuticals Reports 2023 Second Quarter Results and Recent Developments

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that it has filed a new provisional patent application with the United States Patent and Trademark Office (‘USPTO') entitled “NSAID Formulation and Method” related to its Epoladerm™ product candid.

Virpax Pharmaceuticals Files Provisional Patent Application for NSAID Formulation and Method

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax to Ring NASDAQ Closing Bell on July 24, 2023.

Virpax Pharmaceuticals, Inc. to Ring NASDAQ Closing Bell on July 24, 2023

BERWYN, Pa.--(BUSINESS WIRE)-- #earnings--Virpax Reports 2023 First Quarter Results and Recent Developments.

Virpax Pharmaceuticals Reports 2023 First Quarter Results and Recent Developments

LONDON, UK / ACCESSWIRE / April 13, 2023 / Nanomerics Ltd., a private speciality pharmaceutical company today announced that the Company had been granted patent protection in Canada for the ocular use of its Molecular Envelope Technology (MET) drug delivery system.

Nanomerics Announces Ocular Molecular Envelope Technology (MET) Patent Granted in Canada

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced recent progress made in its Envelta development program.

Virpax Reports on Progress of Envelta™

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, announced today that the Company has completed FDA required preclinical toxicology studies for its licensed Molecular Envelope Technology (MET).

Virpax Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology (MET)

BERWYN, Pa.--( BUSINESS WIRE )-- Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, and central nervous system (CNS) disorders, today announced that the Company has engaged New England Investors, LLC to serve as the out-licensing advisor for Envelta in the People's Republic of China. Envelta is Virpax's non-opioid pain product candidate for acute and chronic pain including non-cancer pain.

Virpax Pharmaceuticals Engages New England Investors to Direct Licensing Strategy for Envelta™ in China

BERWYN, Pa.--( BUSINESS WIRE )--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, and central nervous system (CNS) disorders, today announced that it will utilize leading pain expert, Dr. Neil K. Singla, to assist in the design and support of the clinical development strategy for Probudur.

Virpax Pharmaceuticals to Utilize Dr. Neil K. Singla to Assist in Development of Probudur™

BERWYN, Pa.--( BUSINESS WIRE )--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that the Company has engaged Destum Partners, Inc. to serve as the exclusive advisor for the Company's partnering and licensing efforts in strategic global markets. This initial engagement will encompass the Company's two over-the-counter (OTC) product candidates, Epoladerm™, indicated for osteoarthritis pain, and AnQlar™, an intranasal mucosal viral barrier. Additionally, Destum Partners will work with Virpax on identifying a partner in the animal health market for its Rx product candidate, Probudur™, a long-acting local anesthetic indicated for postoperative pain management.

Virpax Pharmaceuticals Engages Destum Partners to Direct Strategic Global Partnering Efforts

BERWYN, Pa.--( BUSINESS WIRE )--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that it has engaged two leading physicians experienced in childhood epilepsy, Dr. Kenneth W. Sommerville and Dr. Lawrence Fried, to support the overall development plan for NobrXiol. Their involvement with this program is expected to include advising on trial design, regulatory pathway development and patient recruitment. Additionally, it is anticipated that they will support Virpax with patient advocacy groups and grant applications.

Virpax Pharmaceuticals Engages Dr. Kenneth W. Sommerville and Dr. Lawrence Fried to Assist in Development of NobrXiol™ (formerly VRP324)

BERWYN, Pa.--( BUSINESS WIRE )--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that it has received pre-Investigational New Drug (PIND) application guidance from the U.S. Food and Drug Administration (FDA) for NobrXiol™, the Company's product candidate for the delivery of cannabidiol in the management of epilepsy in children and adults. NobrXiol utilizes the Nanomerics Molecular Envelope Technology (MET) as its delivery system to cross the blood brain barrier, propelling the cannabidiol nanoparticles through the nose to the brain via the olfactory nerve.

Virpax Pharmaceuticals Reports on FDA Pre-IND Response for NobrXiol™ (formerly VRP324)

Virpax Pharmaceuticals Reports 2022 Third Quarter Results

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that Jeffrey Gudin, MD, will present a poster at the World Congress of World Institute of Pain entitled, “Enkephalin as a Novel Analgesic: Efficiency and Safety in Pre-Clinical Models.” Dr. Gudin

Dr. Jeffrey Gudin, Chief Medical Officer of Virpax Pharmaceuticals, to Present Poster at World Congress of World Institute of Pain

BERWYN, Pa.--(BUSINESS WIRE)-- #earnings--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing non-addictive product candidates for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the quarter ended June 30, 2022, and other recent developments. “We continue to advance our product candidate pipeline focused on pain, CNS and viral barrier ind

News for Virpax Pharmaceuticals Stock (VRPX)